Debunked Episode 25: Sutter Health’s Allina Health Acquisition Strategy, a Deep Dive on Doctronic
Within the newest episode of the Debunked podcast, MedCity Information Editor-in-Chief Arundhati Parmar and Samir Batra, Managing Companion of Well ...
Tag: Acquisition
Eli Lilly’s Neuro Prospects Expand to Sleep Science With $6.3B Centessa Acquisition
Centessa Prescription drugs’ cleminorexton is a part of the orexin agonist drug class, which might introduce a brand new method ...
Merck’s $6.7B Terns Acquisition Positions It to Challenge a Blockbuster Novartis Cancer Drug
Merck has been buying belongings that might assist make up for the approaching income decline as its high product, the ...
Gilead Sciences Gains an Opportunity for Immune System Reset With $1.7B Ouro Acquisition
Gilead Sciences is buying Ouro Medicines, a startup creating T cell engagers for a variety of autoimmune illnesses. Individually, Gilead ...
Vertex Pharma to Seek Speedy FDA Approval for Kidney Disease Drug From $4.9B Acquisition
Povetacicept, a Vertex Prescription drugs immunology drug designed to dam two targets, met the principle purpose of a Section 3 ...
Servier Boosts Presence in Rare Cancers With $2.5B Acquisition of Day One Biopharma
Day One Biopharmaceuticals is Servier’s greatest acquisition but, topping the $2.4 billion it paid to purchase Shire’s most cancers enterprise ...
Revolution Medicines’ CEO faces questions about acquisition
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and ...
Eli Lilly Boosts Its Immunology Drug Pipeline With $1.2B Ventyx Bio Acquisition
Eli Lilly is building its prospects in immunology through the $1.2 billion acquisition of Ventyx Biosciences, a clinical-stage company with ...
Sanofi’s Vaccine Lineup Gets a Shot in the Arm With $2.2B Dynavax Acquisition
Sanofi is boosting its vaccine portfolio and pipeline through the acquisition of Dynavax Technologies, a $2.2 billion deal bringing assets ...
BioMarin’s Presence in Rare Enzyme Disorders Grows With $4.8B Amicus Therapeutics Acquisition
Rare disease drug developer BioMarin Pharmaceutical is buying its way to revenue growth with a $4.8 billion deal for Amicus ...
Discover the latest in health and fitness with Your Health 247. Get expert advice, workout routines, healthy recipes, and mental wellness tips to lead a healthier, happier life. Stay informed and empowered with us!